• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    OpGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    5/29/25 5:20:29 PM ET
    $OPGN
    Medical Specialities
    Health Care
    Get the next $OPGN alert in real time by email
    false 0001293818 0001293818 2024-10-02 2024-10-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    October 2, 2024
    Date of Report (date of earliest event reported)

     

     

     

    OpGen, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   001-37367   06-1614015
    (State or other jurisdiction of
    incorporation or organization)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification Number)

     

    23219 Stringtown Road, Suite 300
    Clarksburg, MD 20871
    (Address of principal executive offices)(Zip code)

     

    (240) 813-1260
    (Registrant's telephone number, including area code)

     

    Not Applicable
    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   OPGN   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On January 2, 2024, AEI Capital Ltd., the Company’s controlling stockholder (“AEI Capital”), entered into a Letter of Engagement with a privately held company (the “Client”), pursuant to which AEI Capital agreed to provide certain listing advisory services relating to the preparation and facilitation of an initial public offering for the Client (the “Engagement Agreement”). In consideration for such services, AEI Capital is entitled to receive a fee consisting of: (i) 2.1% of the outstanding equity interests of the Client (the “Equity Consideration”) and (ii) $120,000 (the “Cash Consideration,” and collectively, with the Equity Consideration, the “Consideration”). The Equity Consideration is payable as follows: (a) 0.5% of the Equity Consideration was paid on October 10, 2024 (the “First Tranche”); (b) 0.4% of the Equity Consideration will be payable after five calendar quarters from the date of the Engagement Agreement; and (c) 1.2% of the Equity Consideration will be payable one month prior to the planned filing of the Client’s application for listing. The Cash Consideration is payable as follows: (1) $60,000 is payable after 14 months from the date of the Engagement Agreement; and (2) $60,000 is payable upon successful completion of the Client’s listing. All Consideration under the Engagement Agreement must be paid within 14 days of the occurrence of the event giving rise to the payment. The Engagement Agreement contains other customary representations, warranties, and agreements of the parties as well as customary indemnification rights and obligations of the Client.

     

    On October 2, 2024, CapForce International Holdings Ltd. (“CapForce”), a limited liability company incorporated in Malaysia and wholly owned subsidiary of OpGen, Inc. (the “Company”), which was organized by the Company for purposes of repositioning itself as a new business in the digital investment banking industry powered by financial technology, entered into an Agreement of Assignment of Mandate with AEI Capital in respect of Direct Listing Sponsorship Advisory Services (the “Assignment Agreement”), pursuant to which AEI Capital assigned all of its rights to the Consideration to CapForce. As a result, in October 2024, AEI Capital transferred and assigned to CapForce the First Tranche of the Equity Consideration. Following the assignment, pursuant to the Assignment Agreement, CapForce anticipates assisting with and performing the services contemplated by the Engagement Agreement.

     

    In addition, on April 3, 2025, CapForce entered into a Joint Venture Agreement (the “JV Agreement”) with the European Credit Investment Bank (“ECIB”), a full-fledged, global facing mid-shore investment bank in Labuan, Malaysia licensed by the Labuan Financial Services Authority, pursuant to which the parties agreed to form a joint venture company named CapForce EC Capital Markets Ltd. (the “Joint Venture”) for purposes of developing and operating a stock trading platform (the “Trading Platform”) and digital investment banking platform across Asia and the rest of the world (the “Digital IB Platform,” and together with the Trading Platform, the “Platforms”). The Platforms encompass (i) a community-focused cross border stock trading platform; (ii) a FinTech-enabled cap table management platform; and (iii) an AI-powered robo-advisory investment bank platform for public listing sponsorship and wealth management. Pursuant to the JV Agreement, CapForce will own 49% of the outstanding equity interests of the Joint Venture, and ECIB will own 51% of outstanding equity interests of the Joint Venture. Under the JV Agreement, the parties agreed to strategically collaborate in order to develop the Platforms. The parties agreed to equally split all profits earned by the Joint Venture and all capital expenditures and operating expenses in the development and operation of the Trading Platform. With respect to operations unrelated to the Trading Platform, CapForce will be entitled to receive 80% of the profits of the Joint Venture if the Joint Ventures revenues are less than $10.0 million or 90% of the profits of the Joint Venture if its revenues exceed $10.0 million. The JV Agreement includes customary representations, warranties, covenants and agreements of the parties, including relating to the responsibilities and obligations of each party in managing and governing the Joint Venture. In particular, CapForce will have the right to appoint two directors to the board of directors of the Joint Venture, and ECIB will have the right to appoint one director to the board of directors of the Joint Venture.

     

    In the JV Agreement, ECIB granted CapForce an option to purchase between 11% and 30% of the equity interests of ECIB held in the Joint Venture. The purchase price for such option and the actual amount of equity interests must be mutually agreed upon by the parties. Upon the formation of the Joint Venture, CapForce will retain contractual control over the Joint Venture, including for accounting consolidation purposes.

     

    The foregoing descriptions of the Engagement Agreement, the Assignment Agreement and the JV Agreement do not purport to be complete and are qualified in their entirety by reference to the complete text of such documents, which are filed as Exhibits 10.1, 10.2 and 10.3 to this Current Report on Form 8-K and incorporated herein by reference.

     

    1

     

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are intended to qualify for the safe harbor from liability established thereunder. Such forward-looking statements are subject to risks and uncertainties that are often difficult to predict, are beyond the Company’s control, and which may cause results to differ materially from expectations, including the risks that the transactions described herein will not be consummated. In addition, for a further discussion of factors that could materially affect the outcome of the Company’s forward-looking statements and its future results and financial condition, see "Risk Factors" in Part I, Item 1A, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and its other reports filed with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    10.1   Letter of Engagement, dated January 2, 2024, between AEI Capital Ltd. and Client.*
    10.2   Agreement of Assignment of Mandate in respect of Direct Listing Sponsorship Advisory Services, dated October 2, 2024, between CapForce International Holdings Ltd. and AEI Capital Ltd.*
    10.3   Joint Venture Agreement, dated April 3, 2025, between the European Credit Investment Bank and CapForce International Holdings Ltd.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

    *Certain portions of this exhibit have been redacted in accordance with Item 601(b)(10) of Regulation S-K.

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: May 29, 2025 OpGen, Inc.
       
      By:

    /s/ John Tan Honjian

        Name: John Tan Honjian
        Title: Chairman and Chief Executive Officer

     

    3

    Get the next $OPGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OPGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Aei Capital Ltd bought $1,916,326,200,000 worth of shares (2,400,000 units at $798,469.25) (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      12/10/24 12:32:18 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • Large owner Aei Capital Ltd bought $11,130,140,980,409 worth of shares (5,245,603 units at $2,121,803.91) (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      10/8/24 6:51:09 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

      ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"), which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all

      5/24/24 4:04:59 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen Announced 1-for-10 Reverse Stock Split

      ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company's existing trading symbol "OPGN." The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 68373L505. OpGen expects that the Reverse Stock Split, which was approved by its stockholders at a Special

      5/16/24 7:00:00 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen Provides Update on Business Operations and Strategic Opportunities

      ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd ("Camtech"), a Singaporean family office for $218,000. The transaction follows Camtech's prior acquisition of all of Curetis GmhH's ("Curetis"), the Company's subsidiary, Unyvero assets, rights and businesses, as part of Curetis' insolvency proceedings. In addition, the Company's subsidiary, Ares Genetics GmbH, sold all of its assets, including the ARESdb database and intellectual property portfolio to bioMerieux S.A., as part of Are

      4/29/24 4:05:00 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    SEC Filings

    See more
    • OpGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - OPGEN INC (0001293818) (Filer)

      5/29/25 5:20:29 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form NT 10-Q filed by OpGen Inc.

      NT 10-Q - OPGEN INC (0001293818) (Filer)

      5/16/25 4:39:39 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form NT 10-K filed by OpGen Inc.

      NT 10-K - OPGEN INC (0001293818) (Filer)

      3/31/25 5:00:19 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer (CTO) Syed Mohd Syed Johan Bin was granted 9,709 shares (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      4/30/25 4:32:10 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Syed Mohd Syed Johan Bin

      3 - OPGEN INC (0001293818) (Issuer)

      4/30/25 4:30:31 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • Director Wong Poh Yin Constance was granted 28,571 shares (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      12/19/24 4:34:06 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Financials

    Live finance-specific insights

    See more
    • OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

      Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract extensionEntered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S.Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 f

      8/10/23 4:15:00 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time

      ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details       U.S. Dial-in Number:   1-877-704-4453       International Dial-in Number: 1-201-389-0920      Webcast:   https://viavid.webcasts.com/starthere.jsp?ei=1618010&tp_key=fc7c8907d6  Re

      8/3/23 7:30:00 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

      Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA submission and Unyvero distribution partnership with Fisher HealthcareMet all remaining key milestones of the FIND collaboration for Unyvero A30Management conference call scheduled for May 15, 2023, at 4:30 p.m. EST ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 20

      5/15/23 4:15:00 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright resumed coverage on OpGen with a new price target

      HC Wainwright resumed coverage of OpGen with a rating of Buy and set a new price target of $4.00

      3/15/21 7:37:07 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • Alliance Global Partners reiterated coverage on OpGen with a new price target

      Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

      3/8/21 8:22:12 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • Alliance Global Partners reiterated coverage on OpGen with a new price target

      Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

      3/2/21 10:53:18 AM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by OpGen Inc.

      SC 13D/A - OPGEN INC (0001293818) (Subject)

      8/1/24 5:25:39 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

      SC 13D/A - OPGEN INC (0001293818) (Subject)

      4/25/24 5:43:11 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

      SC 13D/A - OPGEN INC (0001293818) (Subject)

      4/8/24 4:05:12 PM ET
      $OPGN
      Medical Specialities
      Health Care